Enliven stops work on solid tumor drug; Pulmatrix to divest assetsnews2025-05-15T14:46:10+00:00May 15th, 2025|Endpoints News|
SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39Mnews2025-05-14T15:08:18+00:00May 14th, 2025|Endpoints News|
Axsome’s $570M loan with Blackstone; Altimmune makes its own credit dealnews2025-05-13T14:40:32+00:00May 13th, 2025|Endpoints News|
FDA clears in vivo blood stem cell editing trial; Abeona’s $155M PRV salenews2025-05-12T14:34:12+00:00May 12th, 2025|Endpoints News|
Sanofi scraps IGM deal; Lilly to pay $250M to continue work with Purdue Universitynews2025-05-09T15:20:04+00:00May 9th, 2025|Endpoints News|
ALX Oncology won’t seek approval for CD47 drug in gastric cancer; Korro Bio’s layoffsnews2025-05-08T15:04:16+00:00May 8th, 2025|Endpoints News|
NewAmsterdam’s pooled Phase 3 data; C4 seeks partners for solid tumor degradernews2025-05-07T14:59:33+00:00May 7th, 2025|Endpoints News|
Lilly to pay up to $415M in ALS deal; Actuate’s mid-stage pancreatic cancer datanews2025-05-06T14:44:12+00:00May 6th, 2025|Endpoints News|
Unity lays off ‘all’ workers; Novo to get FDA decision on oral Wegovy this yearnews2025-05-05T14:35:44+00:00May 5th, 2025|Endpoints News|
Kura gets $45M milestone payment from Kyowa Kirin; Pliant’s restructuringnews2025-05-02T14:48:39+00:00May 2nd, 2025|Endpoints News|
